GlaxoSmithKline presents new cancer data at ASH 2017

GlaxoSmithKline has presented clinical data on a promising new cancer therapy at this year's American Society for Hematology (ASH) annual meeting.

During the conference in San Diego, the company shared new phase I/II study data affirming the early promise of GSK2857916, an investigational anti-B-cell maturation antigen antibody-drug conjugate.

Results from the dose expansion phase of the DREAMM-1 study showed that GSK2857916 monotherapy delivered a 60 percent response rate and a median progression-free survival of 7.9 months among heavily pre-treated multiple myeloma patients.

GSK2857916 has already been awarded breakthrough therapy designation from the US Food and Drug Administration and PRIME designation from the European Medicines Agency, showing its potential for addressing significant unmet medical needs.

Axel Hoos, senior vice-president for oncology research and development at GlaxoSmithKline, said: "GSK2857916 is the leading asset in our emerging pipeline of potentially transformative oncology medicines, and we plan to rapidly progress its development programme, initiating pivotal monotherapy studies as well as new combination studies in 2018."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.